Organon & Co | OGN - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Celltrion KRW 140.68B 584.31B 2025-12
Cspc Pharmaceutical CNY 5.91B 512.77M 2025-12
Deva Holding AS TRY 1.35B 178.26M 2023-09
Dianthus Therapeutics USD 69.82M 29.14M 2025-12
Divis Laboratories Ltd INR 20.17B 1.85B 2026-03
Gilead Sciences USD 23.52B 18.55B 2026-03
Glaxosmithkline GBP 9.17B 1.4B 2025-12
Kangmei Pharma CNY 1.39B 144.29M 2025-09
Knight Therapeutics CAD 126.9M 8.29M 2025-12
Laboratorios Farma EUR 313.62M 17.98M 2023-12
Malin Corporation EUR 1.1M 400K 2024-12
Medical Developments International AUD 21.61M 11.59M 2025-12
Merck USD 18.17B 8.01B 2026-03
Neuren Pharmaceuticals AUD 25.23M 16.54M 2025-12
Novartis USD 9.8B 23M 2025-12
Organigram Holdings CAD 83.66M 24.44M 2025-12
Organon & Co USD 903M 387M 2026-03
Ovoca Bio EUR 1.16M 4.48M 2025-06
Pharma Mar EUR 42.28M 4.59M 2026-03
Qiagen NV USD 418.54M 23.25M 2025-12
Sartorius EUR 738.4M 22.4M 2026-03
Sino Biopharmaceutical CNY 12.39B 1.26B 2025-06
Tilray USD 237.52M 17.34M 2025-09
Zealand Pharma A/S 775.97M 265.08M 2025-12